
Why Korea Is Now More Attractive To U.S. Biopharma Why Korea Is Now More Attractive To U.S. Biopharma The U.S. is Korea’s second-largest trade partner. Korea is also one of the top 15 drug markets in the world. Those two facts help explain the import of a ... Life Science Leader 2021.11.01
GENUV Presents Poster at Keystone Symposia GENUV Presents Poster at Keystone Symposia Unveiled Non-preclinical research results on SNR1611, new drug candidate for neurodegenerative diseases At this year’s Keystone Symposia co... Medigate 2021.06.09
GENUV selects Korea Investment & Securities Co.,Ltd. as IPO lead under... GENUV selects Korea Investment & Securities Co.,Ltd. as IPO lead underwriter With steady advancement in the research field of neurodegenerative diseases and immuno-oncology, GENUV aims to go public on KOSDAQ through... Medigate 2021.02.02
GENUV to participate in the 2021 J.P. Morgan Healthcare Conference GENUV to participate in the 2021 J.P. Morgan Healthcare Conference GENUV announced its participation in the upcoming J.P. Morgan Healthcare Conference, which takes place virtually on January 11-14, 202... Medipana 2021.01.05
[Hidden Champions on the Move] GENUV reports continued progress in Lou... [Hidden Champions on the Move] GENUV reports continued progress in Lou Gehrig’s Drug Clinical Trial Innovative drug discovery company, GENUV, announced on December 7th that the phase 1/2a c... Korea SportsBiz 2020.12.08
[Korea Patent Award] GENUV GENUV established "ATRIVIEWTM", a screening platform using neural stem cells for the identification of substances that provide a neuroprotective and differentiating effect on neurons. Through this screening technology, G... Hankook Daily Newspaper 2020.07.18
GENUV to commence P1/2a Clinical Trial for ALS Drug which Shows Effica... GENUV to commence P1/2a Clinical Trial for ALS Drug which Shows Efficacy in Neurogenesis and Neural Homeostasis Recovery 4 hospitals in Korea begin patient recruitment..Comparing safety and efficacy with “Riluzole... BioSpectator 2020.04.20
GENUV, Research for the Development of “Asymmetric Bispecific Antibody... GENUV, Research for the Development of “Asymmetric Bispecific Antibody Platform” Research Collaboration Agreement with Industry University Cooperation Foundation -Hanyang University (Prof. Seong Eon Ryu) &n... BioSpectator 2019.11.21